<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03196557</url>
  </required_header>
  <id_info>
    <org_study_id>IM124-001</org_study_id>
    <nct_id>NCT03196557</nct_id>
  </id_info>
  <brief_title>A Study to Assess the Pharmacodynamics (PD) of Prednisoline in Healthy Male Subject</brief_title>
  <official_title>An Experimental Medicine Study to Assess the Pharmacodynamics Following Administration of Multiple Doses of Prednisolone to Healthy Male Subjects</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Bristol-Myers Squibb</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Bristol-Myers Squibb</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to assess the pharmacodynamics of Prednisolone in healthy male
      subjects
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">March 31, 2008</start_date>
  <completion_date type="Actual">May 5, 2008</completion_date>
  <primary_completion_date type="Actual">May 5, 2008</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Basic Science</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Interleukin 1 beta</measure>
    <time_frame>Up to 32 days</time_frame>
    <description>As measured by flow cytometry</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Tumor necrosis factor-alpha</measure>
    <time_frame>Up to 32 days</time_frame>
    <description>As measured by flow cytometry</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Receptor activator of nuclear factor-kB (RANK)</measure>
    <time_frame>Up to 32 days</time_frame>
    <description>As measured by flow cytometry</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Receptor activator of nuclear factor-kB ligand (RANKL)</measure>
    <time_frame>Up to 32 days</time_frame>
    <description>As measured by flow cytometry</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Osteoprotegrin (OPG)</measure>
    <time_frame>Up to 32 days</time_frame>
    <description>As measured by flow cytometry</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Lipopolysaccharide Induced Cytokine Production</measure>
    <time_frame>Up to 32 days</time_frame>
    <description>As measured by blood concentration</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Cell Populations</measure>
    <time_frame>Up to 32 days</time_frame>
    <description>As measured by flow cytometry</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Oral glucose tolerance test</measure>
    <time_frame>Up to 32 days</time_frame>
    <description>Assessed by central labortatory</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Cortisol</measure>
    <time_frame>Up to 32 days</time_frame>
    <description>As measured by the level of the hormone cortisol in the blood</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Adrenocorticotropic hormone</measure>
    <time_frame>Up to 32 days</time_frame>
    <description>As measured by the level of the hormone in the blood</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Osteocalcin</measure>
    <time_frame>Up to 32 days</time_frame>
    <description>As measured by blood concentration</description>
  </primary_outcome>
  <primary_outcome>
    <measure>N-terminal Pro-Collagen Peptide (PINP)</measure>
    <time_frame>Up to 32 days</time_frame>
    <description>As measured by blood concentration</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Propetide type I C-term Pro-collagen Peptide (CICP)</measure>
    <time_frame>Up to 32 days</time_frame>
    <description>As measured by blood concentration</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Bone-specific alkaline phosphatase</measure>
    <time_frame>Up to 32 days</time_frame>
    <description>As measured by blood concentration</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Urinary deoxypyridinoline</measure>
    <time_frame>Up to 32 days</time_frame>
    <description>As measured by urine concentration</description>
  </primary_outcome>
  <primary_outcome>
    <measure>C Telopeptide of Collagen Type II (CTX-II)</measure>
    <time_frame>Up to 32 days</time_frame>
    <description>As measured by urine concentration</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Calcium</measure>
    <time_frame>Up to 32 days</time_frame>
    <description>As measured by urine concentration</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Creatinine</measure>
    <time_frame>Up to 32 days</time_frame>
    <description>As measured by urine concentration</description>
  </primary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">24</enrollment>
  <condition>Immunoscience</condition>
  <arm_group>
    <arm_group_label>Arm A</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Specified dose on specified days</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Arm B</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Specified dose on specified days</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Prenisolone</intervention_name>
    <description>Specified dose on specified days</description>
    <arm_group_label>Arm A</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>Specified dose on dose on specified days</description>
    <arm_group_label>Arm B</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Healthy male subjects as determined by no clinically significant deviation from normal
             in medical history, physical examination, ECGs, and clinical laboratory determinations

          -  Body Mass Index (BMI) of 18 to 30 kilogram / square meter (kg/m2), inclusive

          -  Signed informed consent

        Exclusion Criteria:

          -  Women

          -  Any significant acute or chronic medical illness

          -  Current or recent (within 3 months) gastrointestinal disease including peptic ulcer

        Other protocol inclusion/exclusion criteria may apply
      </textblock>
    </criteria>
    <gender>Male</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>55 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Bristol-Myers Squibb</last_name>
    <role>Study Director</role>
    <affiliation>Bristol-Myers Squibb</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Local Institution</name>
      <address>
        <city>Austin</city>
        <state>Texas</state>
        <zip>78759</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <link>
    <url>http://www.fda.gov/MEDWATCH/safety.htm</url>
    <description>FDA Safety Alerts and Recalls</description>
  </link>
  <verification_date>June 2017</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>June 21, 2017</study_first_submitted>
  <study_first_submitted_qc>June 21, 2017</study_first_submitted_qc>
  <study_first_posted type="Actual">June 22, 2017</study_first_posted>
  <last_update_submitted>June 21, 2017</last_update_submitted>
  <last_update_submitted_qc>June 21, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">June 22, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

